



- (51) **International Patent Classification:**
G01N 33/574 (2006.01) *G01N 33/50* (2006.01)
- (21) **International Application Number:**
PCT/EP2021/062778
- (22) **International Filing Date:**
13 May 2021 (13.05.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
2007099.1 14 May 2020 (14.05.2020) GB
- (71) **Applicant: KYMAB LIMITED** [GB/GB]; The Bennet Building (B930) Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB).
- (72) **Inventors: SAINSON, Richard, Charles, Alfred;** The Bennet Building (B930) Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). **DEAN-TONIO, Cecilia;** The Bennet Building (B930) Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). **HSU, Chih-Hung;** 5F, No. 2 Xuzhou Road Zhongzheng District, 100 Taipei City (TW). **LU, Li-Chun;** 5F, No. 2 Xuzhou Road Zhongzheng District, 100 Taipei City (TW). **SHERRY, Lorcan, Adrian;** OracleBio Bioc-

ty Scotland, Bo'Ness Road, Motherwell North Lanarkshire ML1 5UH (GB).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


(54) **Title:** TUMOUR BIOMARKERS FOR IMMUNOTHERAPY

Figure 1

(57) **Abstract:** Biomarkers for prognosis of tumours, in hepatocellular carcinoma and other cancers. Measurement of biomarkers for prescription of anticancer immunotherapy targeted against ICOS+ regulatory T cells (TReg), e.g., selecting patients for treatment with an anti-ICOS antibody. Biomarkers comprising: (i) ratio of the number of ICOS FOXP3 double positive cells within a defined radius of influence around ICOS single positive cells to the total number of ICOS single positive cells, (ii) mean distance between each ICOS positive FOXP3 negative cell and its nearest ICOS FOXP3 double positive cell, (iii) proportion of FOXP3 positive cells which are ICOS positive, and (iv) density of ICOS positive cells.

[Continued on next page]

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))